Using antiangiogenic therapy to reduce bleeding in patients with hereditary hemorrhagic telangiectasia
Official title: Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
Funded at Massachusetts General Hospital · NIH-10886041 · Data updated 2026-11-12
This study is looking at whether a medication called bevacizumab can help people with hereditary hemorrhagic telangiectasia (HHT) by reducing bleeding episodes and making their lives better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $199,800 |
| NIH project number | 5K23HL159313-03 |
| Project ID | NIH-10886041 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with hereditary hemorrhagic telangiectasia who experience severe bleeding and are dependent on blood transfusions or iron infusions.
✕Less likely to help
Patients who do not have hereditary hemorrhagic telangiectasia or those who are not experiencing significant bleeding issues may not benefit from this research.
What this research studies
This research investigates the use of an anti-VEGF monoclonal antibody, bevacizumab, to treat hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. The study aims to evaluate the effectiveness of this therapy in reducing severe bleeding episodes and improving the overall quality of life for affected individuals. By conducting a phase II clinical trial, the researchers will gather data on the impact of bevacizumab on bleeding frequency, hemoglobin levels, and patient-reported health outcomes. This approach builds on previous observational studies that showed promising results but lacked standardized methodologies.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly reduces bleeding and improves the quality of life for patients with hereditary hemorrhagic telangiectasia.
How similar studies have gone: Previous observational studies have shown success with bevacizumab in reducing bleeding in HHT, indicating a promising avenue for further investigation.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Al-Samkari, Hanny T — Massachusetts General Hospital
- Study coordinator: Al-Samkari, Hanny T
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.